|
|
Article: ImmunoCellular Therapeutics Presents Data from Phase I Trial of ICT-107 Demonstrating Significant Increase in Tumor-Free Progression in Patients with Brain Cancer.
- Article from:
- Cancer Vaccine Week
- Article date:
- November 9, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ImmunoCellular Therapeutics, Ltd. (OTC: IMUC.OB) (IMUC), a biotechnology company that is focused on the development of novel immune-based cancer therapies, announced additional data from its Phase I clinical trial evaluating ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM). These new data showed a greater progression-free survival time in patients receiving ICT-107 than expected in this patient population. These data were reported at the Congress of Neurological Surgeons Annual Meeting in New Orleans, LA, and supplement the preliminary data presented at the annual meeting of the American ...
Related newspaper, magazine, and journal articles:
|
|
Article: ImmunoCellular Therapeutics Retains Services of ...
Cancer Vaccine Week;
July 27, 2009 ;
700+ words
...ImmunoCellular Therapeutics, Ltd. (OTCBB ... credit (see also ImmunoCellular Therapeutics, Ltd ... Treatment, ImmunoCellular Therapeutics Ltd. This article ... prepared by Cancer Vaccine Week editors ...
|
|